Scoparone inhibits breast cancer cell viability through the NF‑κB signaling pathway

Wu,Xiaoying; Li,Xiaobo; Li,Jing; Zhao,Xinrui; Cui,Yongyuan; Eerdun,Chaolu

doi:10.3892/etm.2023.12027

Scoparone inhibits breast cancer cell viability through the NF‑κB signaling pathway

Authors:
- Xiaoying Wu
- Xiaobo Li
- Jing Li
- Xinrui Zhao
- Yongyuan Cui
- Chaolu Eerdun
View Affiliations

Affiliations: Mongolian Medical College, Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia Autonomous Region 028000, P.R. China, Department of Hematology, Mongolian Medical Hospital, Fuxin Mongolian Autonomous County 123199, P.R. China, Liaoning Boaotaihe Health Technology Co., Ltd., Fuxin, Liaoning 123000, P.R. China, Medical Department, Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia Autonomous Region 028000, P.R. China
Published online on: May 17, 2023 https://doi.org/10.3892/etm.2023.12027
Article Number: 328

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Scoparone (SCO) is a compound found in the stems and leaves of Artemisia capillaris. The pharmacological uses of SCO include significant hypotensive, cholagogic, anti‑inflammatory, analgesic, lipid‑lowering, anti‑asthmatic and anti‑coagulant effects. The present study aimed to verify the anticancer potential of SCO in breast cancer (BC) cells and its underlying molecular mechanism. Cell Counting Kit‑8 and flow cytometry were used to analyze the effects of SCO on cell viability and apoptosis. Nucleocytoplasmic separation was used to analyze the location of the long non‑coding RNA (lncRNA) small nucleolar RNA host gene 12 (SNHG12) in BC cells. Reverse transcription‑quantitative PCR was used to analyze the effect of SCO on the expression levels of SNHG12, microRNA (miRNA/miR)‑140‑3p and tumor necrosis factor receptor associated factor 2 (TRAF2). Western blotting was used to analyze the protein expression levels of TRAF2 and downstream nuclear factor κB (NF‑κB) signaling pathways. The results demonstrated that SCO had a time‑ and dose‑dependent inhibitory effect on the viability of BC cells, and that the upregulated lncRNA SNHG12 in BC cells was inhibited by SCO. SNHG12, which was primarily expressed in the cytoplasm, acted as a competing endogenous RNA, sponged miR‑140‑3p and inhibited the expression of miR‑140‑3p. The transcriptional activity and translational level of TRAF2, a downstream target of miR‑140‑3p, decreased following the SCO‑mediated suppression of SNHG12 expression. As an upstream effector, TRAF2 activity reduction mediated the inhibition of NF‑κB signaling, decreased the viability and migration of BC cells, and promoted BC cell apoptosis. In conclusion, SCO‑induced inhibition of viability and promotion of apoptosis in BC cells are achieved through the inhibition of NF‑κB signaling, which is associated with regulation of the SNHG12/miR‑140‑3p/TRAF2 axis. This understanding provides new drug candidates for the treatment of BC and a theoretical basis for biology.

View Figures

View References

1	Azamjah N, Soltan-Zadeh Y and Zayeri F: Global trend of breast cancer mortality rate: A 25-year study. Asian Pac J Cancer Prev. 20:2015–2020. 2019.PubMed/NCBI View Article : Google Scholar
2	Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017.PubMed/NCBI View Article : Google Scholar
3	Libson S and Lippman M: A review of clinical aspects of breast cancer. Int Rev Psychiatry. 26:4–15. 2014.PubMed/NCBI View Article : Google Scholar
4	Tang JL, Liu BY and Ma KW: Traditional Chinese medicine. Lancet. 372:1938–1940. 2008.PubMed/NCBI View Article : Google Scholar
5	Pei S, Yang X, Wang H, Zhang H, Zhou B, Zhang D and Lin D: Plantamajoside, a potential anti-tumor herbal medicine inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of matrix metalloproteinase-9 and -2. BMC Cancer. 15(965)2015.PubMed/NCBI View Article : Google Scholar
6	Liew AC, Peh KK, Tan BS, Zhao W and Tangiisuran B: Evaluation of chemotherapy-induced toxicity and health-related quality of life amongst early-stage breast cancer patients receiving Chinese herbal medicine in Malaysia. Support Care Cancer. 27:4515–4524. 2019.PubMed/NCBI View Article : Google Scholar
7	Jung SH, Lee GB, Ryu Y, Cui L, Lee HM, Kim J, Kim B and Won KJ: Inhibitory effects of scoparone from chestnut inner shell on platelet-derived growth factor-BB-induced vascular smooth muscle cell migration and vascular neointima hyperplasia. J Sci Food Agric. 99:4397–4406. 2019.PubMed/NCBI View Article : Google Scholar
8	Wang Y, Wang M, Chen B and Shi J: Scoparone attenuates high glucose-induced extracellular matrix accumulation in rat mesangial cells. Eur J Pharmacol. 815:376–380. 2017.PubMed/NCBI View Article : Google Scholar
9	Kim JK, Kim JY, Kim HJ, Park KG, Harris RA, Cho WJ, Lee JT and Lee IK: Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity. PLoS One. 8(e80391)2013.PubMed/NCBI View Article : Google Scholar
10	Kielbus M, Skalicka-Wozniak K, Grabarska A, Jeleniewicz W, Dmoszynska-Graniczka M, Marston A, Polberg K, Gawda P, Klatka J and Stepulak A: 7-substituted coumarins inhibit proliferation and migration of laryngeal cancer cells in vitro. Anticancer Res. 33:4347–4356. 2013.PubMed/NCBI
11	Zhao Z, Guo Y, Liu Y, Sun L, Chen B, Wang C, Chen T, Wang Y, Li Y, Dong Q, et al: Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer. Oncogene. 40:4604–4614. 2021.PubMed/NCBI View Article : Google Scholar
12	Venkatesh J, Wasson MD, Brown JM, Fernando W and Marcato P: LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack. Cancer Lett. 509:81–88. 2021.PubMed/NCBI View Article : Google Scholar
13	Qiao K, Ning S, Wan L, Wu H, Wang Q, Zhang X, Xu S and Pang D: LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway. J Exp Clin Cancer Res. 38(418)2019.PubMed/NCBI View Article : Google Scholar
14	Yuan JH, Li WX, Hu C and Zhang B: Upregulation of SNHG12 accelerates cell proliferation, migration, invasion and restrain cell apoptosis in breast cancer by enhancing regulating SALL4 expression via sponging miR-15a-5p. Neoplasma. 67:861–870. 2020.PubMed/NCBI View Article : Google Scholar
15	Zhou Y, Wang B, Wang Y, Chen G, Lian Q and Wang H: miR-140-3p inhibits breast cancer proliferation and migration by directly regulating the expression of tripartite motif 28. Oncol Lett. 17:3835–3841. 2019.PubMed/NCBI View Article : Google Scholar
16	Sun LL, Wang J, Zhao ZJ, Liu N, Wang AL, Ren HY, Yang F, Diao KX, Fu WN, Wan EH and Mi XY: Suppressive role of miR-502-5p in breast cancer via downregulation of TRAF2. Oncol Rep. 31:2085–2092. 2014.PubMed/NCBI View Article : Google Scholar
17	Taminiau A, Draime A, Tys J, Lambert B, Vandeputte J, Nguyen N, Renard P, Geerts D and Rezsohazy R: HOXA1 binds RBCK1/HOIL-1 and TRAF2 and modulates the TNF/NF-κB pathway in a transcription-independent manner. Nucleic Acids Res. 44:7331–7349. 2016.PubMed/NCBI View Article : Google Scholar
18	Jang KW, Lee KH, Kim SH, Jin T, Choi EY, Jeon HJ, Kim E, Han YS and Chung JH: Ubiquitin ligase CHIP induces TRAF2 proteasomal degradation and NF-κB inactivation to regulate breast cancer cell invasion. J Cell Biochem. 112:3612–3620. 2011.PubMed/NCBI View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
20	Onyeisi JOS, Greve B, Espinoza-Sanchez NA, Kiesel L, Lopes CC and Gotte M: microRNA-140-3p modulates invasiveness, motility, and extracellular matrix adhesion of breast cancer cells by targeting syndecan-4. J Cell Biochem. 122:1491–1505. 2021.PubMed/NCBI View Article : Google Scholar
21	Dou D, Ren X, Han M, Xu X, Ge X, Gu Y, Wang X and Zhao S: Circ_0008039 supports breast cancer cell proliferation, migration, invasion, and glycolysis by regulating the miR-140-3p/SKA2 axis. Mol Oncol. 15:697–709. 2021.PubMed/NCBI View Article : Google Scholar
22	Zamarbide Losada JN, Sulpice E, Combe S, Almeida GS, Leach DA, Choo J, Protopapa L, Hamilton MP, McGuire S, Gidrol X, et al: Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer. J Endocrinol. 256(e220229)2023.PubMed/NCBI View Article : Google Scholar
23	Hua B, Li Y, Yang X, Niu X, Zhao Y and Zhu X: MicroRNA-361-3p promotes human breast cancer cell viability by inhibiting the E2F1/P73 signalling pathway. Biomed Pharmacother. 125(109994)2020.PubMed/NCBI View Article : Google Scholar
24	Jin T, Zhang Y and Zhang T: MiR-524-5p Suppresses migration, invasion, and EMT progression in breast cancer cells through targeting FSTL1. Cancer Biother Radiopharm. 35:789–801. 2020.PubMed/NCBI View Article : Google Scholar
25	Cheng S, Huang Y, Lou C, He Y, Zhang Y and Zhang Q: FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation. Cancer Biol Ther. 20:328–337. 2019.PubMed/NCBI View Article : Google Scholar
26	Gu M, Zhou W, Chen J, Zhao Y, Xie C and Zhou Z: TRAF2 gene silencing induces proliferation and represses apoptosis of nucleus pulposus cells in rats with intervertebral disc degeneration. Life Sci. 279(119670)2021.PubMed/NCBI View Article : Google Scholar
27	Yao Y, Zhao K, Yu Z, Ren H, Zhao L, Li Z, Guo Q and Lu N: Wogonoside inhibits invasion and migration through suppressing TRAF2/4 expression in breast cancer. J Exp Clin Cancer Res. 36(103)2017.PubMed/NCBI View Article : Google Scholar
28	Li QW, Zhang GL, Hao CX, Ma YF, Sun X, Zhang Y, Cao KX, Li BX, Yang GW and Wang XM: SANT, a novel Chinese herbal monomer combination, decreasing tumor growth and angiogenesis via modulating autophagy in heparanase overexpressed triple-negative breast cancer. J Ethnopharmacol. 266(113430)2021.PubMed/NCBI View Article : Google Scholar
29	Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z and Han J: The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 9:16–34. 2015.PubMed/NCBI View Article : Google Scholar
30	Liu B, Deng X, Jiang Q, Li G, Zhang J, Zhang N, Xin S and Xu K: Scoparone improves hepatic inflammation and autophagy in mice with nonalcoholic steatohepatitis by regulating the ROS/P38/Nrf2 axis and PI3K/AKT/mTOR pathway in macrophages. Biomed Pharmacother. 125(109895)2020.PubMed/NCBI View Article : Google Scholar
31	Li N, Yang F, Liu DY, Guo JT, Ge N and Sun SY: Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway. World J Gastrointest Oncol. 13:1164–1183. 2021.PubMed/NCBI View Article : Google Scholar
32	Liu Y, Cheng G, Huang Z, Bao L, Liu J, Wang C, Xiong Z, Zhou L, Xu T, Liu D, et al: Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma. Cell Death Dis. 11(515)2020.PubMed/NCBI View Article : Google Scholar
33	Zhou S, Yu L, Xiong M and Dai G: LncRNA SNHG12 promotes tumorigenesis and metastasis in osteosarcoma by upregulating Notch2 by sponging miR-195-5p. Biochem Biophys Res Commun. 495:1822–1832. 2018.PubMed/NCBI View Article : Google Scholar
34	Ye Y, Ye F, Li X, Yang Q, Zhou J, Xu W, Aschner M, Lu R and Miao S: 3,3'-diindolylmethane exerts antiproliferation and apoptosis induction by TRAF2-p38 axis in gastric cancer. Anticancer Drugs. 32:189–202. 2021.PubMed/NCBI View Article : Google Scholar
35	Wei B, Liang J, Hu J, Mi Y, Ruan J, Zhang J, Wang Z, Hu Q, Jiang H and Ding Q: TRAF2 is a valuable prognostic biomarker in patients with prostate cancer. Med Sci Monit. 23:4192–4204. 2017.PubMed/NCBI View Article : Google Scholar
36	Jiao C, Chen W, Tan X, Liang H, Li J, Yun H, He C, Chen J, Ma X, Xie Y and Yang BB: Ganoderma lucidum spore oil induces apoptosis of breast cancer cells in vitro and in vivo by activating caspase-3 and caspase-9. J Ethnopharmacol. 247(112256)2020.PubMed/NCBI View Article : Google Scholar
37	Poma P: NF-κB and disease. Int J Mol Sci. 21(9181)2020.PubMed/NCBI View Article : Google Scholar
38	Yu H, Lin L, Zhang Z, Zhang H and Hu H: Targeting NF-kappaB pathway for the therapy of diseases: Mechanism and clinical study. Signal Transduct Target Ther. 5(209)2020.PubMed/NCBI View Article : Google Scholar
39	Tan Y, Sun R, Liu L, Yang D, Xiang Q, Li L, Tang J, Qiu Z, Peng W, Wang Y, et al: Tumor suppressor DRD2 facilitates M1 macrophages and restricts NF-κB signaling to trigger pyroptosis in breast cancer. Theranostics. 11:5214–5231. 2021.PubMed/NCBI View Article : Google Scholar
40	Jiang L, Yu L, Zhang X, Lei F, Wang L, Liu X, Wu S, Zhu J, Wu G, Cao L, et al: miR-892b silencing activates NF-κB and promotes aggressiveness in breast cancer. Cancer Res. 76:1101–1111. 2016.PubMed/NCBI View Article : Google Scholar